Membranous Nephropathy

Nephrology·MeSH: Glomerulonephritis, Membranous

13 drugs in development·10 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
alxn1920	ALEXION PHARMACEUTICALS, INC. (ALXN)
Belimumab	ENANTA PHARMACEUTICALS INC (ENTA)
Belimumab	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(4)

Drug	Company
ALXN1920	ARS Pharmaceuticals, Inc. (SPRY)
budoprutug	Climb Bio, Inc. (CLYM)
Felzartamab	BIOGEN INC. (BIIB)
NK Cells	Filana Therapeutics Inc. (FLNA)

Phase 1(3)

Drug	Company
Dual-Target Antigen-Selected CAR-NK	Filana Therapeutics Inc. (FLNA)
EB-SELECT Single-Target CAR-NK Cells	Filana Therapeutics Inc. (FLNA)
povetacicept	VERTEX PHARMACEUTICALS INC / MA (VRTX)

Phase 2/Phase 3(1)

Drug	Company
Tacrolimus	BeOne Medicines Ltd. (ONC)

Phase 4(2)

Drug	Company
Efgartigimod IV	ARGENX SE (ARGX)
efgartigimod iv or efgartigimod ph20 sc	ARGENX SE (ARGX)

BioSniper tracks 13 drugs in development for Membranous Nephropathy across 10 companies.

There are 3 clinical trials targeting Membranous Nephropathy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.